Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Wael Harb, Mansoor N. Saleh, MD, Kyriakos P Papadopoulos, MD, Feng Chai, MD, Maria Larmar, Giovanni Abbadessa, MD, Brian Schwartz, MD, Anthony Tolcher, MD

Blood (2015) 126 (23): 5116.

https://doi.org/10.1182/blood.V126.23.5116.5116

Published: 2015

Journal Articles

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

Michael J Wick, PhD, Elena Helman, PhD, Teresa L Vaught, DVM, Monica Farley, BS, Drew W Rasco, MD, Lon Smith, MD, Anthony Tolcher, MD, Amita Patnaik, MD, Michael Clark, PhD, Kyriakos P Papadopoulos, MD

Blood (2015) 126 (23): 5121.

https://doi.org/10.1182/blood.V126.23.5121.5121

Published: 2015

Journal Articles

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Niranjan S. Rao, PhD, Sanjeeva Reddy, PhD, Gupta Sandeep, PhD, Nitin K Damle, PhD, Venkatesan M Aranapakam, PhD, Scott Thompson, PhD, Roger Smith, PhD, Terry Plasse, MD, Penelope Bristow, MS, Anthony Tolcher, MD, Kyriakos P Papadopoulos, MD, Amita Patnaik, MD, Drew W Rasco, MD

Blood (2015) 126 (23): 4009.

https://doi.org/10.1182/blood.V126.23.4009.4009

Published: 2015

Journal Articles

Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.

Kyriakos Papadopoulos, MD, Alain Mita, MD, Scott Antonio, MD, Lionel D. Lewis, MD, N.J. Reddy, Elizabeth Till, J.J. Mahany, Anne Keating, DPharm, Amanda Seiz, Pamela Bartels, Anthony Tolcher, MD

Blood (2007) 110 (11): 3422.

https://doi.org/10.1182/blood.V110.11.3422.3422

Published: 2007

Journal Articles

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Anthony Tolcher, Thomas Julian, Anila Qureshi

Blood (2007) 110 (11): 4724.

https://doi.org/10.1182/blood.V110.11.4724.4724

Published: 2007

NARROW

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Email alerts

ASH Publications

American Society of Hematology

Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-Inhibitor

Establishment and Characterization of a Patient-Derived Model of ALK-Positive Anaplastic Large Cell Lymphoma

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.

Oblimersen (OBL; Genasense®), a Phosphorothioate (PS) Bcl-2 Antisense Oliogonucleotide (ASO), Can Be Safely Administered by Bolus Subcutaneous (SC) Injection and Brief IV Infusion.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only